Renephra Limited - Period Ending 2019-03-31

Renephra Limited - Period Ending 2019-03-31


Renephra Limited 06815501 false 2018-03-01 2019-03-31 2019-03-31 The principal activity of the company is medical research Digita Accounts Production Advanced 6.24.8820.0 Software true 06815501 2018-03-01 2019-03-31 06815501 2019-03-31 06815501 core:RetainedEarningsAccumulatedLosses 2019-03-31 06815501 core:ShareCapital 2019-03-31 06815501 core:SharePremium 2019-03-31 06815501 core:CurrentFinancialInstruments core:WithinOneYear 2019-03-31 06815501 bus:SmallEntities 2018-03-01 2019-03-31 06815501 bus:AuditExemptWithAccountantsReport 2018-03-01 2019-03-31 06815501 bus:AbridgedAccounts 2018-03-01 2019-03-31 06815501 bus:RegisteredOffice 2018-03-01 2019-03-31 06815501 bus:Director2 2018-03-01 2019-03-31 06815501 bus:Director4 2018-03-01 2019-03-31 06815501 bus:Director6 2018-03-01 2019-03-31 06815501 bus:Director7 2018-03-01 2019-03-31 06815501 bus:PrivateLimitedCompanyLtd 2018-03-01 2019-03-31 06815501 core:Goodwill 2018-03-01 2019-03-31 06815501 core:PatentsTrademarksLicencesConcessionsSimilar 2018-03-01 2019-03-31 06815501 core:ComputerEquipment 2018-03-01 2019-03-31 06815501 4 2018-03-01 2019-03-31 06815501 6 2018-03-01 2019-03-31 06815501 countries:AllCountries 2018-03-01 2019-03-31 06815501 2018-02-28 06815501 2017-03-01 2018-02-28 06815501 2018-02-28 06815501 core:RetainedEarningsAccumulatedLosses 2018-02-28 06815501 core:ShareCapital 2018-02-28 06815501 core:SharePremium 2018-02-28 06815501 core:CurrentFinancialInstruments core:WithinOneYear 2018-02-28 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 06815501

Renephra Limited

Annual Report and Unaudited Abridged Financial Statements

for the Period from 1 March 2018 to 31 March 2019

 

Renephra Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Abridged Financial Statements

4 to 9

 

Renephra Limited

Company Information

Directors

Dr Idalia Lucja Dawidowska

Mr Savvas Ioannou Neophytou

Mr Sandip Mitra

Dr Ian Smith

Registered office

Medtech Centre Greenheys
Manchester Science Park
Pencroft Way
Manchester
M15 6JJ

 

Renephra Limited

(Registration number: 06815501)
Abridged Balance Sheet as at 31 March 2019

Note

2019
£

2018
£

Fixed assets

 

Intangible assets

4

1,260,779

996,061

Tangible assets

5

1,184

895

 

1,261,963

996,956

Current assets

 

Debtors

10,715

10,770

Cash at bank and in hand

 

58,984

163,239

 

69,699

174,009

Prepayments and accrued income

 

12,370

1,992

Creditors: Amounts falling due within one year

(37,445)

(40,667)

Net current assets

 

44,624

135,334

Total assets less current liabilities

 

1,306,587

1,132,290

Accruals and deferred income

 

(40)

(10,790)

Net assets

 

1,306,547

1,121,500

Capital and reserves

 

Called up share capital

4,857

4,147

Share premium reserve

2,460,998

2,323,523

Profit and loss account

(1,159,308)

(1,206,170)

Total equity

 

1,306,547

1,121,500

For the financial period ending 31 March 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

Renephra Limited

(Registration number: 06815501)
Abridged Balance Sheet as at 31 March 2019

Approved and authorised by the Board on 30 December 2019 and signed on its behalf by:
 

.........................................

Dr Idalia Lucja Dawidowska

Director

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Medtech Centre Greenheys
Manchester Science Park
Pencroft Way
Manchester
M15 6JJ

These financial statements were authorised for issue by the Board on 30 December 2019.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Reclassification of comparative amounts

Following a review of the accounting treatment of development costs, a total of £926,334 of costs previously treated as expenditure in the Profit & Loss Account, have been reclassified as capital development costs under the criteria set out in the accounting policy note below.

These costs by year: 2014 - £104,426, 2015 - £258,931, 2016 - £189,698, 2017 - £205,672 and 2018 - £167,608.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

Other grants

Grants are recognised in the financial statements when there has been reasonable assurance that a) the entity will comply with the conditions attaching to the grant; and b) the grants will be received.

The grants are recognised under the performance model, where a grant does not impose specified future performance-related conditions on the recipient is recognised in income when the grant proceeds are received or receivable.

Grants have been recognised in the entity's financial statements at the fair value of the asset received or receivable.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Computer equipment

33.3% Reducing balance

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Intangible assets

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

Development costs

Intangible assets arising from development (or from the development phase of
an internal project) have been recognised if, and only if, an entity can demonstrate all of the following:
a) The technical feasibility of completing the intangible asset so that it will be available for use or sale.
b) Its intention to complete the intangible asset and use or sell it.
c) Its ability to use or sell the intangible asset.
d) How the intangible asset will generate probable future economic benefits. Among other things, the
entity can demonstrate the existence of a market for the output of the intangible asset or the
intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset.
e) The availability of adequate technical, financial and other resources to complete the development and
to use or sell the intangible asset.
f) Its ability to measure reliably the expenditure attributable to the intangible asset during its
development.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

At cost, with impairment reviewed

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 1 (2018 - 1).

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

4

Intangible assets

Total
£

Cost or valuation

At 1 March 2018

996,061

Additions acquired separately

264,718

At 31 March 2019

1,260,779

Amortisation

Carrying amount

At 31 March 2019

1,260,779

At 28 February 2018

996,061

5

Tangible assets

Total
£

Cost or valuation

At 1 March 2018

1,342

Additions

932

At 31 March 2019

2,274

Depreciation

At 1 March 2018

447

Charge for the period

643

At 31 March 2019

1,090

Carrying amount

At 31 March 2019

1,184

At 28 February 2018

895

6

Share capital

Allotted, called up and fully paid shares

 

Renephra Limited

Notes to the Abridged Financial Statements for the Period from 1 March 2018 to 31 March 2019

 

2019

2018

 

No.

£

No.

£

Ordinary of £0.01 each

11,577

115.77

11,577

115.77

Ordinary A of £0.01 each

375,051

3,750.51

304,041

3,040.41

Ordinary B of £0.01 each

99,070

990.70

99,070

990.70

 

485,698

4,857

414,688

4,147